PHR 最新10-Q变化
将 PHR 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-05-28 与上一份 10-Q · 2025-12-09
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +86 | −94 | ~18 | 22 |
| 控制与程序 | 文字有新增/删除 | +2 | −2 | ~1 | 2 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 风险因素 | 文字有新增/删除 | +56 | −58 | ~77 | 161 |
| 其他信息 | 文字有新增/删除 | +1 | −1 | 0 | 0 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):市场风险(第3项)
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-05-28
•Net cash provided by operating activities was $23.9 million for the three months ended April 30, 2026, as compared to $14.9 million for the three months ended April 30, 2025.
•Cash, cash equivalents and restricted cash as of April 30, 2026 was $76.4 million, an increase of $2.6 million as compared to January 31, 2026. As of April 30, 2026, cash, cash equivalents and restricted cash included $1.7 million of long-term restricted cash classified within other long-term asset…
Adjusted EBITDA and Free cash flow are Non-GAAP measures. For a reconciliation of Adjusted EBITDA to net income (loss) and a reconciliation of free cash flow to net cash provided by operating activities, and for more information as to how we define and calculate such measures, see the section below …
We provide an integrated software, payments, and engagement platform designed to address three foundational challenges in healthcare delivery: access to care, affordability of care, and health patient outcomes. Our platform is embedded directly into provider workflows and patient interactions, enabl…
Access: Our solutions facilitate access to care by reducing friction in how patients find, schedule, and register for care, while enabling providers to improve capacity utilization and reduce administrative burden. Key capabilities include care discovery and scheduling through MediFind, our online p…
相对上期删除的文字 · 来源:10-Q · 2025-12-09
•Net income was $1.0 million in the nine months ended October 31, 2025, as compared to net loss of $52.1 million in the nine months ended October 31, 2024.
•Adjusted EBITDA was $72.1 million in the nine months ended October 31, 2025, as compared to $20.4 million in the nine months ended October 31, 2024.
•Net cash provided by operating activities was $15.5 million for the three months ended October 31, 2025, as compared to $5.8 million for the three months ended October 31, 2024.
•Net cash provided by operating activities was $45.2 million for the nine months ended October 31, 2025, as compared to $16.1 million for the nine months ended October 31, 2024.
•Free cash flow was $8.8 million for the three months ended October 31, 2025, as compared to $1.6 million for the three months ended October 31, 2024.
控制与程序
相对上期新增的文字 · 来源:10-Q · 2026-05-28
As required by Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act, our management, including our Chief Executive Officer and our Chief Financial Officer, conducted an evaluation as of the end of the period covered by this Quarterly Report of the effectiveness of the design and operation of our di…
As disclosed in the Notes to Consolidated Financial Statements within our Annual Report on Form 10-K for the fiscal year ended January 31, 2026, we completed the AccessOne Acquisition on November 12, 2025. AccessOne’s total revenues for the three months ended April 30, 2026 constituted approximately…
相对上期删除的文字 · 来源:10-Q · 2025-12-09
As required by Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act, our management, including our Chief Executive Officer and our Chief Financial Officer, conducted an evaluation as of the end of the period covered by this Quarterly Report of the effectiveness of the design and operation of our di…
2025, our disclosure controls and procedures were effective at the reasonable assurance level in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in …
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-05-28
The market for our solutions and services is fragmented, competitive and characterized by rapidly evolving technology standards, evolving regulatory requirements, changes in client needs and the frequent introduction of new products and services, including as a result of AI technologies. Our competi…
and would adversely affect our results of operations. Additionally, if we do not maintain our current client network, or if we have to renegotiate existing contracts on terms less favorable to us, our business, financial condition and results of operations may be harmed.
We believe demand for our solutions and services has been driven in large part by increasing patient responsibility, engagement and consumerism. Our ability to streamline critical workflows in order to improve healthcare services clients’ operations and patient engagement to allow for optimal alloca…
•our ability to obtain meaningful annualized run-rate expense savings from implementing our restructuring plan to reduce operating expenses;
•the extent to which developments in AI may reduce demand for our solutions;
相对上期删除的文字 · 来源:10-Q · 2025-12-09
The market for our products and services is fragmented, competitive and characterized by rapidly evolving technology standards, evolving regulatory requirements, changes in client needs and the frequent introduction of new products and services, including as a result of AI technologies. Our competit…
companies to large, well-financed and technologically-sophisticated entities, including the EHR and PM systems with which we integrate. As costs fall and technology improves, increased market saturation may change the competitive landscape in favor of competitors with greater scale than we currently…
We believe demand for our products and services has been driven in large part by increasing patient responsibility, engagement and consumerism. Our ability to streamline the intake process and critical workflows in order to improve healthcare services organization, staff efficiency and patient engag…
•our ability to hire and retain qualified personnel, including the rate of expansion of our sales force;
In addition, the number of patients utilizing our payment processing tools or consumer financing services offered by our subsidiary, AccessOne MedCard, and the amounts those patients pay directly to our healthcare services clients for services or patients’ need for extended payment plans offered thr…
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-05-28
None of our directors or “officers,” as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, adopted or terminated a Rule 10b5-1 trading plan or arrangement or a non-Rule 10b5-1 trading plan or arrangement, as defined in Item 408(c) of Regulation S-K, during the fiscal quarter covered…
相对上期删除的文字 · 来源:10-Q · 2025-12-09
On September 16, 2025, Yvonne Hui, our Chief Accounting Officer, adopted a trading arrangement for the sale of our common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c). Ms. Hui’s Rule 10b5-1 Trading Plan, which expi…
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议